This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-qua ...
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
News Medical on MSN8h
Vision loss risks in patients using popular GLP-1 medications raise concernsA small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
Newsable Asianet News on MSN22h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-quarter and full-year ...
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback